Astellas to unveil first Phase 1b look at stem cell therapy ASP7317 in GA
The July 15 ASRS presentation offers the first preliminary human data on early visual improvement and safety signals for a stem cell-derived retinal implant in geographic atrophy.
Executive Summary
- Astellas will show the first public human data for its stem cell-derived retinal implant in advanced geographic atrophy, a disease stage where vision loss is already permanent and no therapy restores it.
- Because the underlying trial is open-label, small, and still enrolling, the presentation can indicate early tolerability and functional signals but cannot establish efficacy on its own.
- No trial in geographic atrophy or macular degeneration shares this therapy's cell-replacement mechanism, leaving it without a direct precedent to benchmark against in this indication.
- The trial has pulled its completion timeline in sharply after years of delay and now sits inside its most recent guided window, a sign the study has stabilized operationally even as the science remains unproven.
The presentation
Astellas said the July 15 session will include early signals of potential visual improvement, anatomical stabilization, and patient-reported outcomes for ASP7317 in patients with advanced geographic atrophy secondary to dry age-related macular degeneration. The company described ASP7317 as one of the first pluripotent stem cell-derived ophthalmic cell therapies tested in clinical trials. Marci English, Astellas' senior vice president of biopharma and ophthalmology development, said the company is "pioneering next-generation modalities such as ASP7317, our investigational retinal cell therapy for advanced GA" as part of a broader ambition to address irreversible retinal disease. AstellasAstellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual MeetingJul 9, 2026
The trial behind the data
The data come from NCT03178149, a Phase 1 open-label dose-escalation study that started in July 2018 and targets an anticipated enrollment of 42 patients, with a primary completion date of June 30, 2026. The trial is designed to test the incidence of cellular graft failure or rejection, a safety and tolerability endpoint consistent with an early-phase cell-therapy study rather than an efficacy trial. The study delivers ASP7317 by subretinal injection during vitrectomy surgery, and enrolled patients must be willing to take tacrolimus, an immunosuppressant used to prevent graft rejection. NCT03178149A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationNCT03178149
Timeline history
The trial's primary completion date has moved seven times since a 2020 amendment pushed it from April 2021 to January 2027, before a series of subsequent revisions pulled it back to June 30, 2026 as of a November 2024 amendment. The enrollment target also dropped from 150 to 18 patients in December 2020, then rose back to the current target of 42 in January 2024, alongside a status change from Active-not-recruiting back to Recruiting in August 2022. The trial has run for roughly eight years since its 2018 start. NCT03178149A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationNCT03178149
The competitive field
No trial in the current competitive field for geographic atrophy or age-related macular degeneration shares ASP7317's stem cell-derived RPE replacement mechanism. The nearest modality precedents, OpRegen from Genentech and Famzeretcel from jCyte, are both cell therapies but target different cell populations in different retinal indications, geographic atrophy and retinitis pigmentosa, respectively, and neither is a direct mechanistic comparator. The broader geographic atrophy field is populated instead by complement inhibitors, RNA therapies, and small molecules aimed at slowing lesion growth, such as Regeneron's cemdisiran and Belite Bio's tinlarebant, none of which attempt to replace lost retinal tissue. NCT03178149A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationNCT03178149
What the field lacks
No mechanism has established a disease-modifying benefit that restores vision already lost to geographic atrophy among the comparators in this competitive field, which instead target slowing further lesion growth. Against that backdrop, a cell-replacement approach that shows a graft can survive, integrate, and produce a functional visual signal in patients with existing vision loss would be the result that distinguishes this trial from the slow-the-decline mechanisms surrounding it. The open-label, uncontrolled design and small target enrollment mean any single presentation can indicate a direction worth pursuing further, not establish that effect on its own. NCT03178149A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationNCT03178149
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.